文献速递临床试验与 GCP

在随机对照试验中模拟治疗药物监测结果以进行剂量个体化并维持研究者盲态

Simulating therapeutic drug monitoring results for dose individualisation to maintain investigator blinding in a randomised controlled trial.
PubMed 文献 · Trials · 2017-06-07

该研究在双盲随机对照试验中,由非盲独立统计师利用治疗组实测值模拟安慰剂组药物浓度,并将模拟值与实际值重新盲化后交由剂量调整研究者提出调整建议。共模拟257个假锂血浆浓度,利用242个真实锂血浆浓度实时进行。模拟值中位数(四分位距)为0.59(0.46,0.72),治疗组为0.53(0.39,0.72)。实验室人员和剂量调整研究者的盲态成功维持。

要点

  • 利用治疗组实测值模拟安慰剂组药物浓度,可维持双盲试验中实验室人员和研究者的盲态。
  • 模拟的257个假锂血浆浓度中位数(四分位距)为0.59(0.46,0.72),治疗组242个真实锂血浆浓度为0.53(0.39,0.72)。
  • 模拟值范围较观察数据小,原文归因于药物依从性和给药时间方面的挑战。

核心结论

  • 成功模拟了假锂血浆浓度并维持了盲态。
  • 模拟值范围较观察数据小,原文归因于药物依从性和给药时间方面的挑战。

研究设计与样本

  • 在双盲随机对照试验中,由非盲独立统计师利用治疗组实测值模拟安慰剂组参与者的药物浓度。
  • 模拟值和实际值重新盲化后交由剂量调整研究者,该研究者提出剂量调整建议但不直接负责参与者的临床照护。

主要发现

  • 共模拟257个假锂血浆浓度,利用242个真实锂血浆浓度实时进行。
  • 模拟值中位数(四分位距)为0.59(0.46,0.72),治疗组为0.53(0.39,0.72)。
  • 实验室人员和剂量调整研究者的盲态成功维持。

局限性

  • 模拟值范围较观察数据小,原文归因于药物依从性和给药时间方面的挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Therapeutic drug monitoring (TDM) is essential practice when dosing drugs with a narrow therapeutic index in order to achieve a plasma drug concentration within a narrow target range above the efficacy concentration but below the toxicity concentration. However, TDM with dose individualisation is challenging during a double-blind clinical trial with laboratory staff and investigators blinded to treatment arm allocation. METHODS: Drug concentrations were simulated for participants in the placebo arm by an unblinded independent statistician, utilising the measured values from the treatment arm participants. Simulated and actual concentrations were re-blinded and passed on to a dose-adjusting investigator, who made dose adjustment recommendations but was not directly responsible for clinical care of participants. RESULTS: A total of 257 sham lithium plasma concentrations were simulated utilising 242 true lithium plasma concentrations in real time as the trial progressed. The simulated values had a median (interquartile range) of 0.59 (0.46, 0.72) compared to 0.53 (0.39, 0.72) in the treatment arm. Blinding of the laboratory staff and dose-adjusting investigator was maintained successfully. CONCLUSIONS: We succeeded in simulating sham lithium plasma concentrations while maintaining blinding. Our simulated values have a smaller range than the observed data, which can be explained by the challenges with respect to drug adherence and dose timing that were experienced. TRIAL REGISTRATION: Pan African Clinical Trials Registry, PACTR201310000635418 . Registered on 30 August 2013.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Lesosky M, Joska J, Decloedt E, et al. Simulating therapeutic drug monitoring results for dose individualisation to maintain investigator blinding in a randomised controlled trial. Trials. 2017. PMID: 28592271. doi:10.1186/s13063-017-1992-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。